Marker Therapeutics
Phase 1Harnessing millions of years of immunologic evolution, Marker’s Multi-Antigen Recognizing (MAR) T cell therapy is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications. The MAR-T cell technology provides patients with natural T cells capable of recognizing and killing tumor cells effectively.
About
Harnessing millions of years of immunologic evolution, Marker’s Multi-Antigen Recognizing (MAR) T cell therapy is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications. The MAR-T cell technology provides patients with natural T cells capable of recognizing and killing tumor cells effectively.
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile